Pure Global
NCT00905840

A Study to Treat Patients With Edentulous Mandibles With Two Straumann 3.3mm Diameter Bone Level Implants

A Randomized, Controlled, Double Blind, Clinical Trial to Treat Patients With Edentulous Mandibles With Two Straumann 3.3mm Ø Bone Level Implants by Comparing Two Different Implant Alloys in Split Mouth Design.
Institut Straumann AG·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Jaw, Edentulous
Drug/Device/Intervention
Titanium Zircon implant
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Institut Straumann AG
Location
Leuven,Mainz,Regensburg,Milano,Amsterdam,Groningen,Geneve,Luzern, Belgium,Germany,Italy,Netherlands,Switzerland
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2007
End date
Sep 01, 2011
Enrollment
91 participants
Primary outcome

Change in Crestal Bone Level Between Surgery and 12 Months, to Compare Between the Titan Zircon Implant and the Titan Grade IV Implant.

Summary

The purpose of this study is to assess the change of crestal bone level at the Titanium
 Zirconium (TiZr) compared to Titanium (grade IV) implant between surgery and 6, 12, 24, and
 36 month post surgery.

ICD-10 classifications
Dislocation of jawMottled teethDisorder of gingiva and edentulous alveolar ridge, unspecifiedOther disorders of gingiva and edentulous alveolar ridgeOther specified disorders of gingiva and edentulous alveolar ridge
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00905840
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT00905840 through Pure Global AI's free database. This phase not specified trial is sponsored by Institut Straumann AG and is currently Completed. The study focuses on Jaw, Edentulous. Target enrollment is 91 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.